Ulcerative Colitis
Conditions
Brief summary
This is a Phase I, open-label, single-site trial to evaluate the drug release, using Scintigraphic images and mesalazine plasma levels (PK) in healthy subjects. Overall, nine \[9\] subjects per prototype coating (a total of 18) will be evaluated. Eligible subjects will be assigned in a 1:1 ratio to receive radio-labelled TP05; the first 9 subjects will receive formulation B and the second 9 subjects will receive formulation A. The subjects will be treated once with the radio-labelled study medication.
Interventions
DRUGTP05 Coating A
One radio-labelled tablet given to subjects
DRUGTP05 Coating B
One radio-labelled tablet given to subjects
Sponsors
Tillotts Pharma AG
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy subjects, male or non-pregnant, non-lactating females, between 18 and 55 years old. Females of child bearing potential must have a negative serum pregnancy test prior to the intake of study drug, and must use a hormonal (oral, implantable or injectable) or a double barrier method of birth control throughout the study. Females unable to bear children must have documentation of such in the source records (i.e., tubal ligation, hysterectomy, or post-menopausal \[defined as a minimum of one year since the last menstrual period\]). 2. Ability of subject to participate fully in all aspects of this clinical trial. 3. Voluntarily signed informed consent must be obtained and documented.
Exclusion criteria
1. Participating in a clinical study involving investigational drugs or dosage forms within the previous 2 months. 2. History of alcohol or drug abuse. 3. Radiation exposure from clinical trials, including that from the present study and from diagnostic X-ray but excluding background radiation, exceeds 5 mSV in the last 12 months or 10 mSv in the last 5 years. No subject whose occupational exposure is monitored will participate in the study. 4. Any nuclear medicine procedure prior to study day 1 that might interfere with the scintigraphic images that are acquired. 5. Clinically significant abnormal biochemistry, haematology or urine analyses: * White blood count \< 3 x 109/L and \> 8 x 109/L * Lymphocyte count \< 0.85 x 109/L * Haemoglobin \< 110 g/L * Platelet count \< 125 x 109/L or \> 600 x 109/L * Alanine-Aminotransferase (ALT) or Aspartate-Aminotransferase (AST) \> 2x upper limit normal * Alkaline Phosphatase \> 2x upper limit normal * Serum Creatinine \> upper limit normal 6. History of gastrointestinal surgery, with the exception of appendectomy unless it was performed within the previous 12 months. 7. History of cardiovascular, renal, hepatic, respiratory and particularly gastrointestinal disease, especially peptic ulceration, gastrointestinal bleeding, ulcerative colitis, Crohn's disease or Irritable Bowel Syndrome (within the previous 12 months). 8. History of adverse reaction or allergy to Mesalazine or other salicylates. 9. Acute diarrhoea or constipation in the 14 days before the predicted first study day. If screening occurs \>14 days before first study day, this criterion is to be determined on the first study day. Diarrhoea will be defined as the passage of liquid faeces and/or qa stool frequency of \> 3 times per day. Constipation will be defined as a failure to open the bowels more frequently than every other day. 10. Donation of blood within the previous three months. 11. Positive HBV-Antigen (Hepatitis-B), HCV-Antibody (Hepatitis-C) or HIV-Antibody (Human Immunodeficiency Virus) results. 12. Over-the-counter (OTC) and prescription medication (including laxatives, vitamin-pills and natural herbal remedies) between screening visit (visit 1) and completion of the study. Occasional paracetamol or acetyl-salicyl-acid is permitted. 13. Failure to satisfy the Principle Investigator to participate for any other reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tablet release | 3 days |
Secondary
| Measure | Time frame |
|---|---|
| Maximal Plasma Concentration (Cmax) | 3 days |
| Time to reach Cmax (Tmax) | 3 days |
| Area under the concentration-time curve | 3 days |
| Elimination rate constant (k) | 3 days |
| Lag time (t-lag) | 3 days |
Outcome results
None listed